We use the novel C-DILI™ Assay and Transported Certified™ human hepatocytes to evaluate a compound's potential for cholestatic drug-induced liver injury (DILI).
The C-DILI Assay has demonstrated high in vitro - in vivo correlation with compounds known to have a risk of cholestatic hepatotoxicity. It is an effective tool for assessing the risk of cholestatic DILI and providing data useful in lead selection and managing toxicity risk.
At high concentrations, bile acids can cause liver toxicity by signaling apoptotic pathways as well as disrupting membranes. Bile acid concentrations in the liver are tightly controlled through multiple regulatory mechanisms including canalicular and basolateral efflux, synthesis, and metabolism. However, if control mechanisms are disrupted, bile acid concentrations can reach a "tipping point" resulting in hepatotoxicity. The C-DILI Assay combines all of these human-relevant processes in one simple threshold readout, providing a unique clinically-predictive assessment of cholestasis risk.